Trial Profile
An Observational Registry of Abatacept in Patients With Juvenile Idiopathic Arthritis
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 07 May 2023
Price :
$35
*
At a glance
- Drugs Abatacept (Primary)
- Indications Juvenile rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 07 Feb 2022 Planned number of patients changed from 900 to 800.
- 07 Feb 2022 Planned End Date changed from 31 Dec 2029 to 2 Jan 2029.
- 07 Feb 2022 Planned primary completion date changed from 31 Dec 2029 to 2 Jan 2029.